截至目前，肖立皓先生直接持有公司股份 40,000 股，占公司总股本的 0.0071%，与公司实际控制人、董事肖伟先生系一致行动人，除此以外其与本公 司的董事、高级管理人员及持股 5%以上的股东不存在关联关系，不存在《公司 法》和《公司章程》规定的不得担任公司高级管理人员的情形，未受到中国证券 监督管理委员会的行政处罚或交易所惩戒，不存在上海证券交易所认定不适合担 任上市公司高级管理人员的其他情形，经查询不属于失信被执行人。符合《公司 法》《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等相关法律、 行政法规、规范性文件对公司高级管理人员任职资格的要求。 特此公告。 江苏康缘药业股份有限公司 关于聘任副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏康缘药业股份有限公司（以下简称"公司"）第八届董事会第二十四次 临时会议通知于 2026 年 3 月 28 日以书面文件、电话和电子邮件方式发出，会议 于 2026 年 3 月 30 日在公司会议室以现场结合通讯方式召开。应出席会议董事 11 人，实际出 ...

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has received the clinical trial approval notice for the Black Yellow Chi Zhu granules, which are intended for the treatment of chronic heart failure, indicating a significant step in the drug's development process [1][5]. Group 1: Drug Development and Clinical Trial - The Black Yellow Chi Zhu granules have been approved for clinical trials aimed at treating chronic heart failure, specifically for patients with symptoms such as palpitations, shortness of breath, and fatigue [2][3]. - The drug's mechanism focuses on invigorating qi, promoting blood circulation, and diuresis, addressing the underlying pathophysiology of chronic heart failure [5]. Group 2: Market Context and Need - Chronic heart failure affects approximately 13.7 million patients in China, with a prevalence rate of 1.3% among adults aged 35 and older, indicating a growing need for effective treatments [3]. - Current Western medical treatments for heart failure include various classes of drugs, but many patients experience adverse effects or inadequate responses, highlighting the demand for alternative therapies [4]. Group 3: Future Steps and Market Potential - The company must complete clinical trials and obtain further approvals from the National Medical Products Administration before the Black Yellow Chi Zhu granules can be marketed [5]. - The research and development of this drug are supported by a project from the National Administration of Traditional Chinese Medicine, suggesting a promising clinical value and market potential for the product [5].

Core Viewpoint - Kangyuan Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its product, Black Yellow Red Pearl Granules, which is aimed at treating chronic heart failure caused by ischemic heart disease [1] Company Summary - Kangyuan Pharmaceutical (stock code: 600557) announced the receipt of a clinical trial approval notice for Black Yellow Red Pearl Granules [1] - The granules are indicated for the treatment of symptoms associated with chronic heart failure, including palpitations, shortness of breath, chest tightness, fatigue, and edema [1] Industry Summary - The approval of Black Yellow Red Pearl Granules highlights the ongoing development and regulatory progress in the pharmaceutical industry, particularly in the area of traditional Chinese medicine [1] - The product targets a significant health issue, chronic heart failure, which is prevalent among patients with ischemic heart disease [1]

江苏康缘药业股份有限公司（以下简称"公司"）近日收到国家药品监督管理局 签发的黑黄赤珠颗粒《药物临床试验批准通知书》。按照《上海证券交易所上市公司 自律监管指引第 3 号—行业信息披露》的相关要求，现将相关情况公告如下： | 药品名称 | 黑黄赤珠颗粒 | | --- | --- | | 适应症 | 慢性心力衰竭 | | 注册分类 | 中药创新药 1.1 类 | | 剂型 | 颗粒剂 | | 申请人 | 江苏康缘药业股份有限公司 | | 受理号 | CXZL2500124 | | 通知书编号 | 2026LP00449 | 证券简称：康缘药业 证券代码：600557 公告编号：2026-004 江苏康缘药业股份有限公司 关于收到黑黄赤珠颗粒临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑黄赤珠颗粒功能主治为益气活血、通阳利水。用于缺血性心脏病引起的慢性心 力衰竭气阳虚血瘀水泛证，症见心悸气短、喘息、胸闷、胸痛、疲倦乏力、面肢浮肿、 尿少、咳嗽咯痰、畏寒肢冷、唇甲青紫，烦躁汗出、腹胀等。临床前主要药效 ...

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) has received the Clinical Trial Approval Notice from the National Medical Products Administration for its drug, Heihuangzhizhu Granules, which is aimed at treating chronic heart failure caused by ischemic heart disease [1] Group 1: Drug Information - The drug Heihuangzhizhu Granules is indicated for the treatment of chronic heart failure with symptoms such as palpitations, shortness of breath, chest tightness, fatigue, and edema [1] - Preclinical studies have shown significant improvements in echocardiographic heart function indicators and histopathological results in rat models of chronic heart failure [1] - The drug has demonstrated a notable extension of hypoxia tolerance time in mice and improvements in hemodynamics in anesthetized dogs [1] Group 2: Safety and Efficacy - Toxicological studies indicate that Heihuangzhizhu Granules have good safety profiles in terms of single and repeated dosing, genetic toxicity, and hERG inhibition tests [1] - The drug also exhibits diuretic effects and promotes bronchial secretion in mice [1] Group 3: Regulatory and Development Status - Following the receipt of the clinical trial approval notice, the company must complete clinical trials and obtain review and approval from the National Medical Products Administration before the drug can be produced and marketed [1]

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) has received approval from the National Medical Products Administration for clinical trials of its Heihuangchizhu granules for the treatment of chronic heart failure [1] Group 1 - The company announced the receipt of the clinical trial approval notice on February 25 [1] - The clinical trials will focus on the application of Heihuangchizhu granules in treating chronic heart failure [1]

Core Viewpoint - The company has appointed Mr. Zhang Xiaoliang as the Vice General Manager to strengthen its executive team in response to development needs, following the approval of the board of directors [1]. Group 1: Meeting Details - The notice for the 23rd temporary meeting of the 8th board of directors was sent on February 10, 2026, and the meeting was held on February 14, 2026, with all 11 directors present [1]. - The meeting was conducted in accordance with the Company Law and the company's articles of association, and the appointment of the Vice General Manager was approved unanimously [1]. Group 2: Appointment of Vice General Manager - Mr. Zhang Xiaoliang has been appointed as the Vice General Manager, with his term starting from the date of the board's approval until the end of the current board's term [1]. - Mr. Zhang holds 20,000 shares in the company and has no related party relationships with directors, senior management, or major shareholders [2]. - He meets all qualifications required for senior management positions as per relevant laws and regulations, and has not faced any administrative penalties or disqualifications [2]. Group 3: Background of Mr. Zhang Xiaoliang - Mr. Zhang was born in December 1984, holds a bachelor's degree (currently pursuing a master's), is a member of the Communist Party of China, and is a Chinese national without permanent residency abroad [4]. - He joined the company in 2007 and has held various positions, including Academic Specialist and Regional Manager, and is currently the General Manager of the Southern Infection Division [4].

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has appointed Mr. Zhang Xiaoliang as the new Vice General Manager to strengthen its executive team and meet development needs [1][2]. Group 1: Appointment Details - The appointment was approved unanimously during the 23rd temporary meeting of the 8th Board of Directors held on February 14, 2026 [1]. - Mr. Zhang Xiaoliang's term will last until the end of the current Board's term [1]. Group 2: Candidate Qualifications - Mr. Zhang holds 20,000 shares in the company and has no related party relationships with directors, senior management, or major shareholders [2]. - He meets all qualifications required by the Company Law and relevant regulations, with no administrative penalties or disqualifications from the China Securities Regulatory Commission [2]. Group 3: Candidate Background - Mr. Zhang, born in December 1984, has a bachelor's degree and is currently pursuing a master's degree [4]. - He has been with the company since 2007, holding various positions including Academic Specialist and Regional Manager, and is currently the General Manager of the Southern Infection Division [4].

Group 1 - The core point of the article is that Kangyuan Pharmaceutical has appointed Mr. Zhang Xiaoliang as the new Deputy General Manager to strengthen the executive team and meet the company's development needs [2][3] Group 2 - The appointment was made following the relevant provisions of the Company Law and the company's articles of association [2] - The decision was approved by the company's independent directors in a special meeting [2] - Mr. Zhang's term will last until the end of the eighth board of directors' term [2]

关于聘任副总经理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券简称：康缘药业 证券代码：600557 公告编号：2026-003 江苏康缘药业股份有限公司 特此公告。 江苏康缘药业股份有限公司董事会 2026 年 2 月 24 日 附件：个人简历 张小亮先生：1984 年 12 月出生，本科学历（硕士在读），中共党员，中国 国籍，无境外永久居留权。2007 年进入公司，历任佛山办事处学术专员、感染 广州办地区经理、省区经理、华南事业部总监，现任南区感染事业部总经理职务。 江苏康缘药业股份有限公司（以下简称"公司"）第八届董事会第二十三次 临时会议通知于 2026 年 2 月 10 日以书面文件、电话和电子邮件方式发出，会议 于 2026 年 2 月 14 日在公司会议室以现场结合通讯方式召开。应出席会议董事 11 人，实际出席会议董事 11 人。本次会议的召开符合《公司法》等法律法规以 及《公司章程》的规定。会议由副董事长王振中先生主持，会议以举手和通讯表 决的方式全票审议通过了《关于聘任副总经理的议案》。现将具 ...